Saturday 17 October 2026
Export LIANY’s income statement to Excel — free account
LianBio Sponsored ADR
LIANY Healthcare Biotechnology
0.05
0.00
0.00%
Follow LIANY
| Older periods | Mar '23 | Jun '23 | Sep '23 | Dec '23 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
11.42 | 12.62 | 10.06 | 17.03 |
Net Debt/EBITDA |
11.17 | 10.82 | 9.71 | 25.82 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.73 | 0.89 | 0.66 | 0.82 | |
Capex/Depreciation |
(0.06) | (0.15) | (0.49) | (0.42) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.16) | (0.18) | (0.15) | 2.89 | |
Cash per Share |
2.67 | 2.49 | 2.35 | 5.26 | |
Shareholders Equity per Share |
2.56 | 2.38 | 2.20 | 5.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.56 | 2.38 | 2.20 | 5.39 | |
Free Cash Flow |
(17.65) | (19.37) | (16.02) | 311.83 | |
Working Capital |
270.13 | 251.46 | 232.18 | 577.44 | |
Capital Expenditures |
(0.02) | (0.05) | (0.16) | (0.15) | |
Net Current Asset Value |
267.89 | 249.81 | 231.02 | 576.70 | |
| Other line items | |||||
Quick Ratio |
11.09 | 12.40 | 9.88 | 16.86 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.16) | (0.18) | (0.15) | 2.89 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
4.52 | 4.14 | 4.15 | 20.84 | |
Average Payables |
6.68 | 1.57 | 4.12 | 2.74 | |
Average Assets |
358.03 | 325.31 | 307.37 | 468.96 | |
Average Common Equity |
319.60 | 290.85 | 271.36 | 437.42 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates